Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

ARQT stock hub

Arcutis Biotherapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

ARQTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

2.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

ARQT

In the news

Latest news · ARQT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E70.6

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-1.4

P25 -105.6P50 -46.5P75 -3.1

ROIC0.7

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All ARQT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

228

Groups with data

Currency

USD

Showing 228 of 228 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001787306
Company name	Arcutis Biotherapeutics, Inc.
Country	United States
Country code	US
Cusip	03969K108
Employees	354
Employees Change	12%
Employees Change Percent	3.51
Enterprise value	$2.5B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2020-01-31
Isin	US03969K1088
Last refreshed	2026-05-10
Market cap	$2.6B
Market cap category	Mid-Cap
Price	$21.17
Price currency	USD
Rev Per Employee	1,174,079.1x
Sector	Healthcare
Sic	2834
Symbol	ARQT
Website	https://www.arcutis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-0.09%
EV Sales Forward	4.67x
EV/EBIT	790.13x
EV/EBITDA	464.71x
EV/FCF	94.32x
EV/Sales	6.11x
FCF yield	1.02%
Forward P/E	70.57x
P/B ratio	13.96x
P/S ratio	6.37x
PS Forward	4.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	0.77%
EBITDA Margin	1.31%
FCF margin	6.48%
Gross margin	90.94%
Gross Profit	$378M
Gross Profit Growth	100.93%
Gross Profit Growth Q	67.7%
Gross Profit Growth3 Y	324.82%
Gross Profit Growth5 Y	76.62%
Net Income	$-2.4M
Net Income Growth Quarters	11%
Net Income Growth Years	3%
Pretax Margin	-0.33%
Profit Margin	-0.57%
Profit Per Employee	$-6,712
ROA	0.5
Roa5y	-28.77
ROCE	1.08
ROE	-1.43
Roe5y	-98.85
ROIC	0.72

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	54.57%
Cagr3y	13.29%
Cagr5y	-9.11%
EPS Growth Quarters	12
EPS Growth Years	3
Revenue Growth	95.3x
Revenue Growth Q	60.07x
Revenue Growth Quarters	11x
Revenue Growth Years	3x
Revenue Growth3 Y	300.56x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$1.03
Assets	$460M
Cash	$224M
Current Assets	$438.1M
Current Liabilities	$163.2M
Debt	$114.7M
Debt EBITDA	$18.24
Debt Equity	$0.6
Debt FCF	$4.26
Equity	$189.6M
Interest Coverage	0.24
Liabilities	$270.4M
Long Term Assets	$21.9M
Long Term Liabilities	$107.2M
Net Cash	$109.3M
Net Cash By Market Cap	$4.13
Net Cash Growth	25.25%
Net Debt EBITDA	$-20.01
Net Debt Equity	$-0.58
Net Debt FCF	$-4.06
Tangible Book Value	$175.4M
Tangible Book Value Per Share	$1.4
WACC	12.81

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.68
Inventory Turnover	1.39
Net Working Capital	$58.8M
Quick ratio	2.26
Working Capital	$274.9M
Working Capital Turnover	$1.64

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.7%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	54.53%
200-day SMA	23.04
3Y total return	45.4%
50-day SMA	23.43
50-day SMA vs 200-day SMA	50over200
5Y total return	-37.97%
All Time High	40.88
All Time High Change	-48.21%
All Time High Date	2020-03-20
All Time Low	1.76
All Time Low Change	1,102.84%
All Time Low Date	2023-12-01
ATR	1.2
Beta	1.58
Beta1y	0.77
Beta2y	0.85
Ch YTD	-27.1
High	21.36
High52	31.77
High52 Date	2025-12-08
High52ch	-33.36%
Low	20.26
Low52	12.72
Low52 Date	2025-06-13
Low52ch	66.43%
Ma50ch	-9.65%
Premarket Change Percent	0.63
Premarket Price	$20.79
Premarket Volume	5,066
Price vs 200-day SMA	-8.11%
RSI	38.3
RSI Monthly	54.4
RSI Weekly	42.59
Sharpe ratio	0.96x
Sortino ratio	1.73
Total Return	-2.7%
Tr YTD	-27.1
Tr1m	-9.02%
Tr1w	-9.34%
Tr3m	-22.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	6
Analyst Count Top	4
Analyst Price Target Top	$35
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.05
Earnings Revenue Estimate	102,758,800x
Earnings Revenue Estimate Growth	56.06x
Operating Income	$3.2M
Operating margin	0.77
Price target	$34
Price Target Change	$60.61
Price Target Change Top	$65.33

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	92,960,174%
Float Percent	74.32%
Shares Insiders	1.61%
Shares Institutions	81.93%
Shares Out	125,083,374
Shares Qo Q	-4.62%
Shares Yo Y	2.7%
Short Float	17.84%
Short Ratio	12.57
Short Shares	13.26

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-14.4M
Average Volume	1,414,666.05x
Bv Per Share	1.52
CAPEX	$-78,000
Ch1m	-9.02
Ch1w	-9.34
Ch1y	54.53
Ch3m	-22.51
Ch3y	45.4
Ch5y	-37.97
Ch6m	-12.63
Change	2.47%
Change From Open	2.22
Close	20.66
Days Gap	0.24
Depreciation Amortization	2,250,000
Dollar Volume	57,475,025.8
Earnings Date	2026-05-06
Earnings Time	amc
EBIT	$3.2M
EBITDA	$5.5M
EPS	$-0.02
F Score	6
FCF	$26.9M
FCF EV Yield	1.06x
FCF Per Share	$0.22
Financing CF	7,645,000
Fiscal Year End	December
Founded	2,016
Income Tax	$985,000
Investing CF	-53,335,000
Ipr	24.53
Iprfo	-8.16
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-06
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-25
Ma150	25.27
Ma150ch	-16.24%
Ma20	23.44
Ma20ch	-9.68%
Net CF	-18,651,000
Next Earnings Date	2026-08-05
Open	20.71
Optionable	Yes
P FCF Ratio	98.38
P OCF Ratio	98.1
Position In Range	82.73
Post Close	21.17
Postmarket Change Percent	-0.61
Postmarket Price	$21.04
Ppne	5,401,000
Pre Close	20.66
Price Date	2026-05-08
Price EBITDA	$485
Ptbv Ratio	15.1
Relative Volume	1.92x
Revenue	415,624,000x
SBC By Revenue	9.93x
Share Based Comp	41,276,000
Tax By Revenue	0.24x
Tr6m	-12.63%
Us State	California
Volume	2,714,928
Z Score	3.59

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does ARQT pay a dividend?

Capital-return profile for this ticker.

Performance

ARQT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns ARQT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+81.9%

Float: +74.3% of shares outstanding

Insider ownership

+1.6%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

ARQT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

38.3

Neutral momentum band

Price vs 200-day MA

-8.1%

50/200-day relationship not available

Beta (5Y)

1.58

More volatile than the market

Sharpe ratio

0.96

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About ARQT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current ARQT stock rating?

Arcutis Biotherapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full ARQT analysis?

The full report lives at /stocks/ARQT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for ARQT?

The latest report frames ARQT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the ARQT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.